Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: A case report

Keyphrases

• Nivolumab 100%
• Melanoma 100%
• Remitting Seronegative Symmetrical Synovitis with pitting Edema 100%
• Immune Checkpoint Inhibitors 83%
• Corticosteroids 50%
• Immune Checkpoint Inhibitor Therapy 50%
• Orally Administered 33%
• Moderate to Severe 16%
• Malignancy 16%
• Immune Response 16%
• Knee 16%
• Inflammatory Arthritis 16%
• Metastatic Melanoma 16%
• Ultrasound 16%
• Serological Test 16%
• Wheelchair 16%
• High Incidence 16%
• Abrupt Cessation 16%
• Salvage Therapy 16%
• Activities of Daily Living 16%
• Symptom Onset 16%
• Both Hands 16%
• Therapy Discontinuation 16%
• Soft Tissue Swelling 16%
• Excellent Response 16%
• Independent Functioning 16%
• Pitting Edema 16%
• Stable Control 16%
• Low-dose Corticosteroids 16%
• Prior-independent 16%
• Flexor Tenosynovitis 16%
• White People 16%
• Plain Film 16%
• 70 Years Old 16%
• Immune-related Adverse Effects 16%

Medicine and Dentistry

• Synovitis 100%
• Immune Checkpoint Inhibitor 100%
• Nivolumab 100%
• Edema 100%
• Melanoma 100%
• Low Drug Dose 25%
• Cancer 12%
• Rheumatoid Arthritis 12%
• Clinician 12%
• Metastatic Melanoma 12%
• Limited Mobility 12%
• Salvage Therapy 12%
• Side Effect 12%
• Case Presentation 12%
• Tenosynovitis 12%
• Inflammatory Arthritis 12%
• Adverse Effect 12%